From gastric inflammation to gastric cancer

Digestive Diseases

Volumn 28, Issue 4-5, 2010, Pages 609-614

  Bornschein, Jan ^a   Kandulski, Arne ^a   Selgrad, Michael ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gastric cancer; Gastritis; Gene polymorphism; Helicobacter pylori; Regulatory T cells

Indexed keywords

CAGA PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; VACUOLATING TOXIN; VIRULENCE FACTOR;

BACTERIAL VIRULENCE; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE COURSE; DNA POLYMORPHISM; GASTRITIS; GENETIC SUSCEPTIBILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK FACTOR; STOMACH CANCER; STOMACH MUCOSA;

GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; STOMACH; STOMACH NEOPLASMS; VIRULENCE FACTORS;

EID: 78649398923     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320061     Document Type: Conference Paper

References (72)

1. Parkin DM, Bray F, Ferlay J, et al: Globa l cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Schmidt N, Peitz U, Lippert H, et al: Missing gastric cancer in dyspepsia. Aliment Pharmacol Ther 2005; 21: 813-820.
3. Coleman MP, Gatta G, Verdecchia A, et al: EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14(Suppl 5):v128-v149.
4. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. I ARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
5. Watanabe T, Tada M, Nagai H, et al: Helico-bacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 1998; 115: 642-648.
6. Honda S, Fujioka T, Tokieda M, et al: Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res1998; 158:4255-4259.
7. Sugiyama A, Maruta F, Ikeno T, et al: Helico-bacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcino-genesis in the Mongolian gerbil. Cancer Res 1998; 15,58:2067-2069.
8. Yao Y, Tao H, Park DI, et al: Demonstration and characterization of mutations induced by Helicobacter pylori organisms in gastric epithelial cells. Helicobacter 2006; 11: 272-286.
9. Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 13, 345: 784-789.
10. Huang JQ, Sridhar S, Chen Y, et al: Meta-analysis of the relationship between Helico-bacter pylori seropositivity and gastric cancer. Gastroenterolog y 1998; 114 : 1169-1179.
11. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-353.
12. Ekstrom AM, Held M, Hansson LE, et al: He-licobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121:784-791.
13. Salama N, Guillemin K, McDaniel TK, et al: A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc Natl Acad Sci USA 2000; 19,97: 14668-14673.
14. Enroth H, Kraaz W, Engstrand L, et al: Heli-cobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 20 00; 9: 981-985.
15. Peek RM Jr, Crabtree JE: Helicobacter infection and gastric neoplasia. J Pathol 2006; 208: 233-248.
16. Parsonnet J, Friedman GD, Orentreich N, et al: Risk for gastric cancer in people with Cag Apositiveor Cag Anegative Helicobacter pylori infection. Gut 1997; 40:297-301.
17. Backert S, Ziska E, Brinkmann V, et al: Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2000; 2:155-164.
18. Odenbreit S, Puls J, Sedlmaier B, et al: Trans-location of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000; 25,287: 1497-1500.
19. Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4:688-694. (Pubitemid 39215067)
20. Higashi H, Tsutsumi R, Muto S, et al: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 25,295:683-686.
21. Tsutsumi R, Higashi H, Higuchi M, et al: Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. J Biol Chem 2003; 278: 3664-3670.
22. Brandt S, Kwok T, Hartig R, et al. : NF-k appaB activation and potentiation of proinflam-matory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 2005; 102: 9300-9305.
23. Kim H, Lim JW, Kim KH: Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor-kappaB. Scand J Gastroenterol 2001; 36:706-716.
24. Kindlund B, Sjoling A, Hansson M, et al: FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric meta-pla si a a n d a re a s sociate d t o CD4(+) T- cel l aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. He-licobacter 2009; 1 4 : 192-201.
25. Atherton JC, Peek RM Jr, Tham KT, et al: Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotox-ingene of Helicobacter pylori. Gastroenterol-ogy 1997; 112:92-99.
26. Cover TL, Blanke SR: Helicobacter pylori VacA, a paradigm for toxin multifunctional-ity. Nat Rev Microbiol 2005; 3:320-332.
27. Galmiche A, Rassow J, Doye A, et al: The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J 200 0; 19 : 63 61-6370.
28. Goll R, Gruber F, Olsen T, et al: Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa. Helicobacter 2007; 12: 18 5-192.
29. Kuck D, Kolmerer B, Iking-Konert C, et al: Vacuolating cytotoxin of Helicobacter pylori induces apoptosis in the human gastric epithelial cell line AGS. Infect Immun 2001; 69: 5080-5087.
30. Gebert B, Fischer W, Weiss E, et al: Helico-bacter pylori vacuolating cytotoxin inhibits T lymphocy te activation. Science 2003; 301: 1099-1102.
31. Atherton JC, Cao P, Peek RM, et al: Mosa-icism in vacuolating cytotoxin alleles of He-licobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771-17777.
32. Prinz C, Hafsi N, Voland P: Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol 2003; 11 : 134-138.
33. Rad R, Gerhard M, Lang R, et al: The Helico-bacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. J Immunol 2002; 16 8 : 3033-3041.
34. Gerhard M, Lehn N, Neumayer N, et al. : Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 1999; 96:12778-12783.
35. Crabtree JE, Shallcross TM, Heatley RV, et al: Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32:1473-1477.
36. Hou L, El-Omar EM, Chen J, et al: Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogen-esis 2007; 28:118-123. (Pubitemid 44942634)
37. Machado JC, Pharoah P, Sousa S, et al: Inter-leukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121:823-829.
38. Santini D, Angeletti S, Ruzzo A, et al: Tolllike receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008; 154:360-364.
39. Wex T, Ebert MP, Kropf S, et al: Gene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in Germany. Anticancer Res 2008; 28: 757-762.
40. El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
41. Crusius JB, Canzian F, Capella G, et al: Cy-tokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol 2008; 19: 1894-1 902.
42. Kamangar F, Cheng C, Abnet CC, et al: Interleukin-1B polymorphisms and gastric cancer risk - a meta-analysis. Cancer Epidemiol Biomarkers Prev 20 06; 15: 1920 -1928. (Pubitemid 44664269)
43. Camargo MC, Mera R, Correa P, et al: Inter-leukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1674-1687.
44. Vincenzi B, Patti G, Galluzzo S, et al: Inter-leukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. Oncol Rep 2008; 20:1213-1220.
45. Wang P, Xia HH, Zhang JY, et al: Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer 2007; 120:552-562.
46. Machado JC, Figueiredo C, Canedo P, et al: A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125:364-371.
47. Gao LB, Rao L, Wang YY, et al: The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009; 30: 295-299.
48. Canedo P, Corso G, Pereira F, et al: The in-terferon gamma receptor 1 (IFNGR1) -56C/ T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 2008; 57: 1504-1508.
49. Hold GL, Rabkin CS, Chow WH, et al: A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905-912.
50. Wex T, Bornschein J, Malfertheiner P: Host polymorphisms of immune regulatory genes as risk factors for gastric cancer. Minerva Gastroenterol Dietol 2009; 55: 395-4 08.
51. Gonzalez CA, Riboli E: Diet and cancer prevention: where we are, where we are going. Nutr Cancer 2006; 56: 225-231.
52. D'Elios MM, Andersen LP: Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter 2009; 1:21-28.
53. Lohoff M, Rollinghoff M, Sommer F: Helico-bacter pylori gastritis: a Th1 mediated disease? J Biotechnol 2000; 83:33-36.
54. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
55. Kandulski A, Malfertheiner P, Wex T: Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer. Anticancer Res 2010; 30:1093-1103.
56. Jang TJ: The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract 2010; 206: 34-38.
57. Kandulski A, Wex T, Kuester D, et al: Naturally occurring regulatory T cells (CD4+, CD25high, FOXP3+) in the antrum and car-dia are associated with higher H. pylori colonization and increased gene expression of TGF-beta1. Helicobacter 2008; 13: 295-303.
58. Robinson K, Kenefeck R, Pidgeon EL, et al: Helicobacter pylori -induced peptic ulcer disease is associated w it h i nadequate reg ulator y T cel l responses. Gut 2008; 57: 1375-1385.
59. Enarsson K, Lundgren A, Kindlund B, et al: Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcino-ma. Clin Immunol 2006; 121: 358-368.
60. Shen LS, Wang J, Shen DF, et al: CD4(+) CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 20 09; 131: 109-118.
61. Wang SK, Zhu HF, He BS, et al: CagA+ H. pylori infection is associated with polarization of T helper cell immune responses in gastric carcinogenesis. World J Gastroenter-ol 2007; 13: 2923-2931.
62. Perrone G, Ruffini PA, Catalano V, et al: In-tratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44: 1875-1882.
63. Fuccio L, Zagari RM, Eusebi LH, et al: Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 21; 151: 121-128.
64. Wong BC, Lam SK, Wong WM, et al: Helico-bacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-19 4.
65. Lochhead P, El-Omar EM: Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007; 21:281-297.
66. Take S, Mizuno M, Ishiki K, et al: The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100:1037-1042.
67. Ohata H, Kitauchi S, Yoshimura N, et al: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 10 9: 138-143.
68. Domellof L: Reversal of gastric atrophy after Helicobacter pylori eradication: is it possible or not? Am J Gastroenterol 1998; 93: 14 0 7- 140 8.
69. Mabe K, Ta ka hashi M, Oizu m i H, et al. : Doe s Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 2009; 15:4290-4297.
70. Watari J, Das KK, Amenta PS, et al: Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hep-atol 2008; 6:409-417.
71. Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. La ncet 2008; 372: 392-397.
72. Wu CY, Kuo KN, Wu MS, et al: Early Helico-bacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137:1641-1648.